Lupin has informed that it has enclosed is a Press Release on 17th June 2021 as regards receipt of USFDA approval for the Company’s Sevelamer Hydrochloride Tablets, 400 mg and 800 mg to market a generic equivalent of Renagel Tablets, 400 mg and 800 mg, of Genzyme Corporation. This may be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The above information is a part of company’s filings submitted to BSE.
